Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$4.39 +10.6%	$3.18	$1.03 ▼ $4.53	$850.92M	1.54	6.27 million shs	6.96 million shs
DNA Ginkgo Bioworks	$11.73 +1.2%	$11.48	$5.00 ▼ $16.85	$686.12M	1.5	1.64 million shs	1.02 million shs
MDWD MediWound	$17.39 -0.3%	$19.34	$14.14 ▼ $22.50	$188.49M	0.21	74,797 shs	72,921 shs
OCS Oculis	$17.80 +1.4%	$18.41	$10.79 ▼ $23.08	$766.28M	0.27	11,697 shs	2,529 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	0.00%	-1.98%	+12.46%	+96.53%	+203.05%
DNA Ginkgo Bioworks	-3.09%	-13.35%	+2.48%	+68.95%	-23.78%
MDWD MediWound	+0.52%	-6.99%	-13.10%	-14.26%	-7.48%
OCS Oculis	-2.23%	-2.53%	+0.29%	-2.23%	+46.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	2.8663 of 5 stars	3.7	3.0	2.2	1.7	0.6
DNA Ginkgo Bioworks	0.8965 of 5 stars	1.2	3.0	1.2	2.5	0.6
MDWD MediWound	1.4758 of 5 stars	3.4	1.0	0.9	0.8	0.6
OCS Oculis	3.1194 of 5 stars	3.5	5.0	3.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.40	Buy	$11.25	156.26% Upside
DNA Ginkgo Bioworks	2.33	Hold	$8.50	-27.52% Downside
MDWD MediWound	2.80	Moderate Buy	$32.25	85.45% Upside
OCS Oculis	3.00	Buy	$35.33	98.50% Upside

Current Analyst Ratings Breakdown

Latest MDWD, OCS, DNA, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	MDWD MediWound	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/8/2025	DNA Ginkgo Bioworks	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/30/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $15.00
7/29/2025	ATAI atai Life Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
7/28/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	3,035.33	N/A	N/A	$0.67 per share	6.55
DNA Ginkgo Bioworks	$227.04M	3.06	N/A	N/A	$10.35 per share	1.13
MDWD MediWound	$20.22M	9.30	N/A	N/A	$1.86 per share	9.35
OCS Oculis	$780K	996.34	N/A	N/A	$1.91 per share	9.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.69	N/A	N/A	N/A	N/A	-85.43%	-64.38%	N/A
DNA Ginkgo Bioworks	-$547.03M	-$5.86	N/A	N/A	N/A	-136.56%	-43.25%	-22.29%	N/A
MDWD MediWound	-$30.22M	-$2.64	N/A	N/A	N/A	-142.18%	-96.71%	-39.73%	N/A
OCS Oculis	-$97.43M	-$2.64	N/A	N/A	N/A	-13,788.70%	-92.95%	-70.03%	8/21/2025 (Estimated)

Latest MDWD, OCS, DNA, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	OCS Oculis	-$0.53	-$0.5168	+$0.0132	-$0.59	$0.14 million	$0.25 million
8/14/2025	Q2 2025	ATAI atai Life Sciences	-$0.12	-$0.14	-$0.02	-$0.14	N/A	$0.72 million
8/14/2025	Q2 2025	MDWD MediWound	-$0.55	-$1.23	-$0.68	-$1.23	$5.68 million	$5.71 million
8/7/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	-$1.10	+$0.34	-$1.10	$41.60 million	$49.60 million
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.02	4.02	4.07
DNA Ginkgo Bioworks	N/A	5.41	5.41
MDWD MediWound	N/A	1.48	1.99
OCS Oculis	N/A	4.79	4.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
DNA Ginkgo Bioworks	78.63%
MDWD MediWound	46.83%
OCS Oculis	22.30%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
DNA Ginkgo Bioworks	9.72%
MDWD MediWound	9.20%
OCS Oculis	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	214.34 million	156.90 million	Optionable
DNA Ginkgo Bioworks	640	59.20 million	53.45 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable

MDWD, OCS, DNA, and ATAI Headlines

Recent News About These Companies

Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates

5 hours ago | zacks.com

Oculis Reports Q2 2025 Financial Results and Provides Company Update

August 21 at 4:05 PM | globenewswire.com

Oculis Reports Q2 2025 Financial Results and Provides Company Update

August 21 at 4:05 PM | globenewswire.com

Uncovering Potential: Oculis Holding's Earnings Preview

August 20 at 10:59 PM | benzinga.com

Aberdeen Group plc Boosts Stake in Oculis Holding AG $OCS

August 20 at 5:27 AM | marketbeat.com

Oculis (OCS) Expected to Announce Quarterly Earnings on Tuesday

August 20 at 2:54 AM | marketbeat.com

Oculis (OCS) to Release Quarterly Earnings on Thursday

August 20 at 2:30 AM | americanbankingnews.com

322,500 Shares in Oculis Holding AG (NASDAQ:OCS) Purchased by SR One Capital Management LP

August 19 at 8:07 AM | marketbeat.com

Oculis Holding AG (NASDAQ:OCS) Short Interest Down 54.1% in July

August 19 at 5:11 AM | marketbeat.com

Privosegtor shows functional, anatomical improvements in patients with optic neuritis

August 12, 2025 | healio.comH

Oculis Holding AG to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 12, 2025 | quiverquant.comQ

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 12, 2025 | globenewswire.com

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

August 12, 2025 | globenewswire.com

Oculis Holding AG Secures Amended Loan Agreement with Kreos Capital

August 2, 2025 | msn.com

Oculis Holding AG Amends Loan Facility with BlackRock to Enhance Financial Flexibility

August 1, 2025 | quiverquant.comQ

Oculis Upsized Loan Facility to Access up to CHF 100 million

August 1, 2025 | globenewswire.com

Oculis Upsized Loan Facility to Access up to CHF 100 million

August 1, 2025 | globenewswire.com

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

July 9, 2025 | globenewswire.com

OCS - Oculis Holding AG Executives - Morningstar

July 5, 2025 | morningstar.comM

Oculis Holding AG (OCS) - Yahoo Finance

June 28, 2025 | sg.finance.yahoo.com

Oculis Publishes Results of 2025 Annual General Meeting

June 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD, OCS, DNA, and ATAI Company Descriptions

atai Life Sciences NASDAQ:ATAI

$4.39 +0.42 (+10.58%)

Closing price 04:00 PM Eastern

Extended Trading

$4.36 -0.02 (-0.57%)

As of 07:59 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Ginkgo Bioworks NYSE:DNA

$11.73 +0.14 (+1.18%)

Closing price 03:59 PM Eastern

Extended Trading

$11.86 +0.14 (+1.18%)

As of 07:44 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

MediWound NASDAQ:MDWD

$17.39 -0.05 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$17.40 +0.00 (+0.03%)

As of 07:50 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Oculis NASDAQ:OCS

$17.80 +0.25 (+1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$18.12 +0.32 (+1.83%)

As of 05:09 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time